orphenadrine has been researched along with Long QT Syndrome in 1 studies
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a woman, affected by congenital long QT syndrome (LQTS), who experienced three syncopal episodes shortly after the assumption of a low dose of orphenadrine." | 7.73 | Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. ( Luzza, F; Oreto, G; Raffa, S; Saporito, F, 2006) |
| "We report the case of a woman, affected by congenital long QT syndrome (LQTS), who experienced three syncopal episodes shortly after the assumption of a low dose of orphenadrine." | 3.73 | Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. ( Luzza, F; Oreto, G; Raffa, S; Saporito, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luzza, F | 1 |
| Raffa, S | 1 |
| Saporito, F | 1 |
| Oreto, G | 1 |
1 other study available for orphenadrine and Long QT Syndrome
| Article | Year |
|---|---|
Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine.
Topics: Aged; Electrocardiography; Female; Humans; Long QT Syndrome; Muscarinic Antagonists; Orphenadrine; T | 2006 |